Smau is the matching platform for innovation and professional continuous training. For over 50 years, Smau supports Italian companies and professionals to innovate, and it is an opportunity for entrepreneurs, managers, companies, and public administrations to grow up and to catch up on innovation, technology, and ICT. Smau is a national event roadshow helping public actors and companies willing to look beyond the present and opportunities offered by new technologies, digital world, and most promising start ups.
The event of this year is also dedicated to the synergies among research centres, companies and public funding in the Life Sciences areas as experienced in Fas Salute 2014 Call of Tuscany Region which UNAVIR is belonging to.
UNAVIR is a project aimed at identifying new therapeutic treatments for rare viral infections, such as Dengue, Chikungunya and West Nile and brings together Universities of Siena, Pisa, and Florence and companies, Lead Discovery Siena and VisMederi, to develop innovative treatments of personalised medicine. LDS will contribute to the projects by supporting the design, synthesis and ADMET characterization of new molecular entities active against these virues.
Maurizio Botta, LDS CEO, was the rapporteur on this project at Smau Florence to show its background, the research strategy and its potentialities.
Maurizio Botta, LDS CEO, gives an interview on a popular television programme in Italy, dedicated to health and welfare.
Maurizio talks about the project on DDX3 inhibitors as antiviral agents active against HIV and Hepatitis C, among the others.
Maurizio’s research group together with the Molecular Genetics Institute of CNR in Pavia, identified the first molecules targeting DDX3, a human protein involved in the replication of many viral pathogens. During its interview, Maurizio outlines the innovative strategy which underpins the research project on DDX3 inhibitors, and recalls the history of this exciting discovery which mainly involved Italian research groups.
LDS is now taking part to the development of these broad spectrum antiviral agents thanks to its expertise and competences in discovery and development.
The show aired on 23th May 2016.
Maurizio Botta, and researchers from University of Siena and LDS, were really honoured they had the chance to tell their story about DDX3 to the Italian Nobel Prize winner Dario Fo.
The Italian recipient of the 1997 Nobel Prize in Literature, Dario Fo, and his wife Franca Rame, privately contributed to support the DDX3-inhibitor project through the Rame-Fo Foundation. Soon after the publication of the important results achieved in the project, and published in PNAS publication, Dario Fo expressed his enthusiasm about it in his web page:
Unfortunately, Franca Rame passed away before learning the results of her efforts but the researchers working on DDX3 are all incredibly grateful for her support and for believing in this pioneering project.
On 6th May, Dario Fo invited the researchers working in the DDX3 Project for a meeting at the “Libera Università di Alcatraz” founded by his son Jacopo Fo and they spent a wonderful day they’ll never forget with him. Here is a video about the interview.
All the DDX3 researchers would like to express a huge thank you to Dario Fo and to his group for all the effort and the great support to this work, which LDS is also actively contributing to. This is a really precious endorsement for all of them.